石药集团：乙磺酸尼达尼布吸入粉雾剂 在中国获临床试验批准
CSPC PHARMACSPC PHARMA(HK:01093) Jin Rong Jie·2026-01-02 12:10

Core Viewpoint - The approval of the inhalation powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement for the treatment of idiopathic pulmonary fibrosis (IPF) in the country, being the first inhalation formulation approved for clinical trials in China [1] Group 1 - The inhalation powder formulation of Nintedanib has received approval for clinical trials in China [1] - Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF) [1] - The currently available formulation of Nintedanib is an oral soft capsule [1]